CoChat

Exosomal PD-L1 contributes to immunosuppression and is associated with anti-PD-1 response

Open access

The DOI matches its Crossref record; 33 of the 33 references it cites were found in a registry or an index.

Abstract

Tumour cells evade immune surveillance by upregulating the surface expression of programmed death-ligand 1 (PD-L1), which interacts with programmed death-1 (PD-1) receptor on T cells to elicit the immune checkpoint response 1,2. Anti-PD-1 antibodies have shown remarkable promise in treating tumours, including metastatic melanoma 2-4. However, the patient response rate is low 4,5. A better understanding of PD-L1-mediated immune evasion is needed to predict patient response and improve treatment efficacy. Here we report that metastatic melanomas release extracellular vesicles, mostly in the form of exosomes, that carry PD-L1 on their surface. Stimulation with interferon-γ (IFN-γ) increases the amount of PD-L1 on these vesicles, which suppresses the function of CD8 T cells and facilitates tumour growth. In patients with metastatic melanoma, the level of circulating exosomal PD-L1 positively correlates with that of IFN-γ, and varies during the course of anti-PD-1 therapy. The magnitudes of the increase in circulating exosomal PD-L1 during early stages of treatment, as an indicator of the adaptive response of the tumour cells to T cell reinvigoration, stratifies clinical responders from non-responders. Our study unveils a mechanism by which tumour cells systemically suppress the immune system, and provides a rationale for the application of exosomal PD-L1 as a predictor for anti-PD-1 therapy.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/s41586-018-0392-8

Cites

33 of 33 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 33 references

Cited by

See all 2,813

Metadata

Authors
Chen, G., Huang, A. C., Zhang, W., Zhang, G., Wu, M., Xu, W., Yu, Z., Yang, J., Wang, B., Sun, H., Xia, H., Man, Q., Zhong, W., Antelo, L. F., Wu, B., Xiong, X., Liu, X., Guan, L., Li, T., Liu, S., Yang, R., Lu, Y., Dong, L., McGettigan, S., Somasundaram, R., Radhakrishnan, R., Mills, G., Lu, Y., Kim, J., Chen, Y. H., Dong, H., Zhao, Y., Karakousis, G. C., Mitchell, T. C., Schuchter, L. M., Herlyn, M., Wherry, E. J., Xu, X., & Guo, W.
Affiliations
  • University of Pennsylvania (US)
  • Wuhan University (CN)
  • The Wistar Institute (US)
  • Abramson Cancer Center (US)
  • The University of Texas MD Anderson Cancer Center (US)
  • Mayo Clinic (US)
Corresponding author
  • Xu, Wei
  • Xu, Xiaowei
  • Guo, Wei
Venue
Nature
Published
2018-08
Volume
560
Issue
7718
Pages
382-386
ISSN
  • 0028-0836 (ISSN-L)
  • 1476-4687
OpenAlex
W2887249435
Cited by
2,813
References
33
Citations by year
2026: 258 · 2025: 325 · 2024: 422 · 2023: 382 · 2022: 398 · 2021: 416 · 2020: 365 · 2019: 212 · 2018: 30
FWCI
96.20
Type
journal article
Language
en
Open access
Licence
www.springer.com/tdm (tdm)
Locations
  • Nature (publishedVersion)
  • PubMed (publishedVersion)
  • Europe PMC (PubMed Central) (acceptedVersion)
  • PubMed Central (acceptedVersion)
  • RePEc: Research Papers in Economics (submittedVersion)
Funders
  • National Cancer Institute (R01CA047159, P01CA114046, U54CA193417, P01CA025874, P50CA174523, T32CA009615, P30CA010815)
  • National Institute of General Medical Sciences (R01GM111128, R01GM085146)
  • National Institute of Allergy and Infectious Diseases (R01AI105343, U19AI117950, U19AI082630, P01AI108545)
Topics
  • Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Extracellular vesicles in disease
  • Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
Keywords
exosomal PD-L1, exosomes, metastatic melanoma, immune checkpoint evasion, PD-1/PD-L1 interaction, anti-PD-1 therapy, interferon-gamma, CD8+ T cell suppression, tumor immune evasion, predictive biomarkers, treatment response stratification, circulating exosomes
MeSH terms
Antineoplastic Agents, Immunological, Animals, Female, Humans, Immune Tolerance, Interferon-gamma, Melanoma, Mice, Nude, Neoplasm Metastasis, Prognosis, Case-Control Studies, CD8-Positive T-Lymphocytes, Disease Progression, Tumor Escape, Xenograft Model Antitumor Assays, Cell Line, Tumor, Mice, Exosomes, B7-H1 Antigen, Programmed Cell Death 1 Receptor, Antibodies, Monoclonal, Humanized

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Exosomal PD-L1 contributes to immunosuppression and is associated with anti-PD-1 response. https://app.cochat.ai/papers/10.1038/s41586-018-0392-8
The paper
Chen, G., Huang, A. C., Zhang, W., Zhang, G., Wu, M., Xu, W., Yu, Z., Yang, J., Wang, B., Sun, H., Xia, H., Man, Q., Zhong, W., Antelo, L. F., Wu, B., Xiong, X., Liu, X., Guan, L., Li, T., . . . Guo, W. (2018). Exosomal PD-L1 contributes to immunosuppression and is associated with anti-PD-1 response. Nature. https://doi.org/10.1038/s41586-018-0392-8

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.